Vasoactive Inotrope Score as a Predictor of Postoperative Complications in Cancer Surgery Patients-A Prospective Observational Study

血管活性正性肌力评分作为癌症手术患者术后并发症预测指标——一项前瞻性观察研究

阅读:1

Abstract

In this study, we evaluated Vasoactive Inotrope score (VIS) for prognosis in onco-surgery patients and determine whether there is correlation between VIS and grade of complication (according to Modified Clavien-Dindo Classification). This prospective observational study was conducted at Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India. The setting conducted at a tertiary care referral centre. The participants aged 18-65 years, undergoing major abdominopelvic and thoracic onco-surgeries, requiring vasopressor and ionotropic support in an intensive care unit from May 2022 to February 2023, were recruited into the study. Thus, 257 patients were enrolled. Patients were given noradrenaline, adrenaline, vasopressin, dopamine, and dobutamine. Patients, on other vasopressor infusions, who lost to follow-up and are not willing to participate in the study were excluded. The following are the main outcome(s) and measure(s): Initial Vasoactive Inotrope score (VIS(0)), maximum Vasoactive Inotrope score (VIS(max)), and grade of complication. VIS(max) has significant positive correlation (r = 0.147; p = 0.01) with grade of complication. Both VIS(0) and VIS(max) have a significant positive correlation with length of ICU stay (r = 0.164, p = 0.001; r = 0.242, p = 0.001). Also there is a significant Odds Ratio (OR = 1.068; 95% CI = 1.004-1.136; p = 0.036) of patient having ≥ Grade 3 complication if VIS(max) increases by a unit. A cutoff of VIS(max) > 5.1 had a sensitivity of 82.1% and specificity of 33.5% (p = 0.014) to predict ≥ Grade 3 complications. VIS(max) may be helpful in predicting higher grade of complication and length of ICU stay in onco-surgery patients. This study is the very first one to evaluate VIS in cancer patients; further studies would help in strengthening the findings. Trial Registration: CTRI/2022/09/045237; www.ctri.nic.in.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。